News & Events
Disc Medicine Appoints Will Savage, MD, PhD as Chief Medical Officer and Jonathan Yu as Chief Business Officer and Expands Scientific Leadership with Key Hires to Advance Clinical-Stage Pipeline
Company welcomes Dr. Hua Yang, PhD, as VP, Nonclinical Development and Clinical Pharmacology and Sarah Tuller, JD as VP, Regulatory Affairs CAMBRIDGE, Mass. (August 23, 2021) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for
More News
Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic...
read more
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from...
read more
Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
read more